Pharmacy Sermorelin · The reference cabinet
Sermorelin, filed under its own name
I opened this subject expecting a tidy entry for a familiar peptide. Instead, I met a former childhood medicine surrounded by results from its relatives. The names matter more than the family resemblance.
The Sermorelin peptide
Sermorelin copies the first 29 amino acids of growth hormone-releasing hormone, or GHRH, whose full human form has 44. Those 29 retain full activity at the GHRH receptor. It is an unusually economical fragment: a shorter version of the body's message can still prompt the pituitary to release growth hormone. The review of GHRH and its analogues places that fragment in a much larger family.
A secretagogue simply prompts a secretion. Here the secretion is growth hormone, followed by insulin-like growth factor 1, usually shortened to IGF-1, which the liver produces in response. That sequence explains the blood-test changes in the papers; the more ambitious claims about vitality and aging need evidence of their own.
A former pediatric medicine
The older clinical literature describes diagnostic testing and treatment of childhood growth-hormone deficiency. That history deserves more space than it usually gets. In the multicenter childhood trial, first-year growth accelerated from about 4.1 cm/year to roughly 7-8 cm/year without excessive IGF-1 generation. The population was prepubertal children with growth-hormone deficiency.
The approved U.S. product left the market in 2008 for commercial reasons, rather than a safety or effectiveness problem. A clinical review of the resulting gap in GHRH testing records the practical aftermath. The specificity of that past appeals to me; the later reputation seems much harder to pin down.
Sermorelin acetate and compounding
Sermorelin acetate is the salt form of the peptide. The study material was supplied as freeze-dried powder because aqueous peptide solutions are susceptible to degradation. Preparation and stability are part of the pharmacokinetic record, although they tell us little about the outcomes people hope for.
Under the FDA's interim Section 503A compounding policy, whose final guidance was issued in January 2025, sermorelin is treated as a Category 1 bulk substance while review continues. A compounded sermorelin medicine has no FDA approval. The former approval, the later commercial withdrawal and the current compounding policy describe different things.
Nearby entries
Tesamorelin supplies some of the most striking results encountered in this literature, including the cognition trial in older adults. MR-409 and MR-502 appear in the skin-cell and wound-healing experiments. Their names deserve to travel with their findings. It tests my patience when the family name GHRH quietly turns all of them into sermorelin.
The Sermorelin vs Tesamorelin comparison gives the clinical records room side by side. The mechanism entry follows the short signal and its longer hormone response. For the unexpected cell, animal and computer leads, open the later sections of the research cabinet.
Sleep and energy accounts
Accounts of deeper sleep, more energy, puffiness and disappointing results circulate around sermorelin. These are anecdotal accounts, not clinical evidence; those accounts provide no reliable denominator from which to calculate a chance of benefit or harm. The reported-effects page takes those accounts seriously enough to describe them without turning them into a trial.
Those awkward experiments have my vote over broad wellness language. One especially awkward finding is that continuous GHRH delivery in children eventually produced a declining hormone response. A plausible mechanism still has to survive contact with the way it was tested.